Insider Selling: DexCom CFO Sells 8,000 Shares of Stock (DXCM)
DexCom (NASDAQ:DXCM) CFO Jess Roper unloaded 8,000 shares of the stock on the open market in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $36.01, for a total transaction of $288,080.00. Following the completion of the sale, the chief financial officer now directly owns 87,786 shares of the company’s stock, valued at approximately $3,161,174. The sale was disclosed in a legal filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on DXCM shares. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, June 27th. They now have a $42.00 price target on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of DexCom from $38.00 to $40.00 in a research note on Tuesday, June 17th. They now have a “buy” rating on the stock. Finally, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the stock. DexCom currently has an average rating of “Hold” and a consensus target price of $39.60.
Shares of DexCom (NASDAQ:DXCM) traded up 2.38% during mid-day trading on Tuesday, hitting $37.83. The stock had a trading volume of 485,322 shares. DexCom has a 52-week low of $21.76 and a 52-week high of $49.83. The stock’s 50-day moving average is $37.76 and its 200-day moving average is $38.27. The company’s market cap is $2.834 billion.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.17) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter last year, the company posted ($0.16) earnings per share. DexCom’s revenue was up 59.1% compared to the same quarter last year. On average, analysts predict that DexCom will post $-0.33 earnings per share for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.